Compare Amgen, Inc. (AMGN) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Zillow Group Inc Class C — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Zillow Group Inc Class C trades at $32.46 (market cap $7.36B). The key difference: Amgen, Inc. is far larger — about 26.6× Zillow Group Inc Class C's market cap, and Amgen, Inc. pays a 2.77% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| AMGN | Z | |
|---|---|---|
Market Cap | $196.12B | $7.36B |
Sector | Health | Media |
52-Week High | $388.16 | $90.35 |
52-Week Low | $271.18 | $29.41 |
Enterprise Value | $241.41B | $7.00B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Zillow Group (Z) trades at $32.19, down 3.74% on the day. The stock shows mixed technical signals with a neutral overall stance. Fundamentally, the company reported revenue of $2.58 billion in 2025 with a net income of $23 million, marking a return to profitability. However, a high P/E ratio of 128.76 indicates significant growth expectations are priced in. Recent news is dominated by multiple securities class action lawsuits filed against the company.
The outlook is clouded by legal risks, though analyst consensus remains optimistic with a $63 price target. The primary opportunity lies in the company's strong revenue growth and high gross margins, but investors must weigh this against the overhang from litigation and the stock's demanding valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
